Drug intelligence / Profile preview

insulin lispro Mix25 + insulin lispro Mix50

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

This drug is a combination of two biphasic premixed insulins used for the management of diabetes mellitus. Each component is itself a fixed-ratio mixture: - **Insulin lispro Mix25** contains 25% rapid-acting insulin lispro solution and 75% intermediate-acting insulin lispro protamine suspension. - **Insulin lispro Mix50** contains 50% rapid-acting insulin lispro solution and 50% intermediate-acting insulin lispro protamine suspension. Both are recombinant DNA-derived human insulins designed to provide both prandial (mealtime) and basal (background) glycemic control. Insulin lowers blood glucose by facilitating cellular uptake of glucose in muscle and fat tissue while inhibiting hepatic glucose production. The combination provides flexibility in matching individual patient needs for mealtime coverage versus basal requirements[1][2][8][9].

Brand names
Humalog Mix 25Humalog Mix 50Humalog Mix 25 KwikPenHumalog Mix 50 KwikPen
Other names
insulin lispro protamine and insulin lispro (Mix25)insulin lispro protamine and insulin lispro (Mix50)
02

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on insulin lispro Mix25 + insulin lispro Mix50.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin lispro Mix25 + insulin lispro Mix50.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call